Lung cancer (Amsterdam, Netherlands)HumansCarcinomaNon-Small-Cell LungLung NeoplasmsNeoadjuvant Therapy
Attrition with adjuvant, neoadjuvant, and perioperative immunotherapy-based treatment protocols in patients with resectable non-small-cell lung cancer. A meta-analysis of prospective trials.
Francesco Guerrera, Filippo Tommaso Gallina, Eleonora Balzani, Francesca Ambrosi, Alessandro Di Federico, Eleonora Faccioli, Giorgio Facheris, Roberto Ferrara, Alessandra Ferro, Federica Filipello, Raffaele Giusti, Carlo Greco, Marco Mammana, Daniele Marinelli, Antonio Nuccio
Published: 202510.1016/j.lungcan.2025.108760
Abstract
BACKGROUND: The use of immunotherapy (IOT) in treating non-small-cell lung cancer (NSCLC) has revolutionized care standards. However, full compliance with neoadjuvant, perioperative, and adjuvant treatment protocols remains a challenge. This study ai…
Preview only. Read the full abstract at the source